---
title: MedTech Startup Exit Strategy: M&A, IPO, and Strategic Partnerships
description: MedTech exits look different from SaaS exits. Here is the M&A, IPO, and partnership reality for MedTech startups in Europe.
authors: Tibor Zechmeister, Felix Lenhard
category: Funding, Business Models & Reimbursement
primary_keyword: MedTech startup exit strategy
canonical_url: https://zechmeister-solutions.com/en/blog/medtech-exit-strategy
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# MedTech Startup Exit Strategy: M&A, IPO, and Strategic Partnerships

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **A MedTech startup exit strategy is the plan for how founders and investors convert ownership into cash or liquid equity. In European MedTech, three paths dominate: trade sale to a strategic acquirer, initial public offering, and a strategic partnership that functions as a de facto exit through buy-in clauses or option agreements. M&A is by far the most common. IPOs are rare and expensive. Partnerships are the quiet third path that many founders underestimate. Regulatory assets — CE certificates, a live QMS, a clean technical file — are part of the valuation, not a side note.**

**By Felix Lenhard and Tibor Zechmeister. Last updated 10 April 2026.**

---

## TL;DR

- MedTech exits are dominated by trade sales to strategic acquirers. IPOs exist but are rare in Europe and expensive to reach. A strategic partnership with a buy-in path is the underrated third route.
- Acquirers in MedTech buy three things at once: a product, a regulatory asset, and a team. The regulatory asset is often what makes the deal possible on the acquirer's timeline.
- CE certificates and a live QMS under EN ISO 13485:2016+A11:2021 are transferable assets, but the transfer is not automatic and needs to be planned into the deal.
- IPO timing in European MedTech is rarely the right primary exit plan for a startup — the window is narrow, the cost is high, and the public-market appetite for pre-profit MedTech is unstable.
- The founder dilemma is real: the right exit for the founder is often not the right exit for every investor on the cap table. Decide early whose interests the plan optimises for.
- The common mistake is waiting until an offer lands to think about exit structure. By then the leverage has already moved to the acquirer.

---

## Why founders should think about exit before they need to

The first time most MedTech founders think seriously about exit is the morning after an acquirer calls. That is too late. By then the acquirer has decided what the company is worth, has a template term sheet, and has a regulatory due diligence checklist ready. The founder is reacting, not planning.

The founders who get good exits think about the shape of the exit years earlier. Not because they are in a hurry to sell — most are not — but because the decisions you make about regulatory strategy, cap table, clinical evidence, and intellectual property all constrain or enable the exits that are still available to you later. A founder who built the company assuming a trade sale to a large strategic, then discovers at year four that the only realistic acquirer is a competitor the founder does not want to sell to, is in a hard place. A founder who built the company with multiple exit paths preserved has leverage.

This post is not a pitch to sell. It is the map of what exits in European MedTech actually look like, what acquirers actually care about, and what regulatory work has to be in place before any serious exit conversation starts.

## The three exit modes

There are really only three exits that matter for MedTech startups in Europe, even though the glossy startup press talks about more.

**Trade sale — mergers and acquisitions.** A larger company — often a strategic in the same therapeutic area, sometimes a private equity-backed platform, occasionally a distributor moving upmarket — buys the startup. This is by far the most common exit path in European MedTech. The acquirer wants the product, the regulatory status, the team, the customer relationships, and the intellectual property. Deal structures range from all-cash to cash-plus-earn-out to share swaps, and the earn-out clause is usually where the most important negotiation happens.

**Initial public offering — IPO.** The company lists on a public exchange. In European MedTech, this is rare. Euronext Growth, the Frankfurt Börse, Nasdaq First North, London's AIM — these exist, and some MedTech companies use them, but the appetite for pre-profit MedTech on European public markets is volatile. The cost of listing is high. The compliance burden after listing is real. For most early-stage MedTech startups, IPO is not a primary exit plan — it is a remote optionality preserved for a future that may or may not arrive.

**Strategic partnership as exit.** The third path is the one founders underestimate. A larger company enters a partnership — exclusive distribution, co-development, licensing — with a structured buy-in or buy-out clause that triggers at specific milestones. In practice, this is a phased acquisition with training wheels. The acquirer tests the relationship for 12–24 months, then exercises the option. The founder gets early liquidity, reduced risk, and a path to full exit without the uncertainty of a single-shot M&A process. This structure is more common in European MedTech than founders realise, and it often produces better outcomes for both sides than a pure trade sale would.

These three are not mutually exclusive. Many MedTech companies pursue two or three in parallel, letting the market decide which one actually closes. The mistake is to fixate on one path early and plan everything around it, only to discover later that the path was never going to open.

## What acquirers look for in MedTech

The question founders should be asking a year before any real conversation starts is: what would make a serious acquirer actually want to buy this company? The answer has a consistent shape in MedTech, and it is different from the SaaS answer.

An acquirer in MedTech is buying four things at once. First, a product that works — engineering quality, clinical performance, a clean user experience. Second, a regulatory status that is current and transferable — CE certificate valid, technical documentation clean, QMS under EN ISO 13485:2016+A11:2021 operating and audited, PMS data landing, no open non-conformities. Third, a team with the specific know-how the product depends on — regulatory lead, clinical lead, the engineers who understand the design history. Fourth, the market position — revenue if it exists, a credible reimbursement story, customer references, distribution relationships.

The regulatory asset is often the component that decides whether the deal closes on the acquirer's timeline. An acquirer can build a sales force and hire engineers. An acquirer cannot wait 18 months for a Notified Body to re-issue a certificate under new ownership. The founders who understand this build their regulatory work to be acquirable — documented, traceable, portable — long before any acquirer appears.

What acquirers do not buy is potential wrapped in mess. A company with a good product, a messy QMS, a technical file full of gaps, and three open non-conformities will either not sell or will sell at a heavy discount, because the acquirer is pricing in the cost and risk of fixing the regulatory debt themselves. Clean beats clever at exit.

## Regulatory assets as part of the valuation

This is the part of MedTech exits that SaaS founders never have to think about, and that MedTech founders should think about constantly.

A CE certificate is a transferable asset, but the transfer is not automatic. When a MedTech company is acquired, the acquirer usually wants the certificates to continue to apply to the product under new ownership. In practice, this means the acquirer either takes over the legal manufacturer role — with all the MDR Article 10 obligations that come with it — or the product is re-branded under the acquirer's existing quality system. Either path is doable, but both require planning and both involve the Notified Body. The Notified Body has to be notified of the change. The QMS has to be updated. The technical documentation has to follow.

A live, audited QMS under EN ISO 13485:2016+A11:2021 is itself a significant asset. Building a new QMS from scratch takes many months and substantial money. Inheriting a working one accelerates the acquirer's integration timeline dramatically. Acquirers know this, and sophisticated ones price it into the offer.

The technical file is the third transferable asset. A complete, well-organised, current technical file is worth real money at exit because it represents years of work that the acquirer does not have to redo. A technical file full of gaps, outdated references, or unresolved findings is a liability — the acquirer will insist on fixing it before closing, on the founder's time and budget, which compresses the seller's leverage in final negotiations.

The practical rule: treat your regulatory work as an asset register from day one. Every document, every audit, every certificate, every PMS datapoint is building the asset that will be valued at exit. This reframes how you spend on compliance. It is not just cost of doing business. It is capital expenditure on something that will eventually be priced.

## IPO timing reality

Most MedTech founders who mention IPO as an exit plan have not actually looked at the European IPO market for pre-profit MedTech in the last few years. When they do, the plan usually changes.

The reality is that the European public markets have narrow, unstable windows for MedTech listings. When the window is open — strong sentiment for health-tech, a receptive investor base, comparable listings performing well — a listing is possible but still expensive. When the window is closed, which is most of the time for pre-profit companies, listing is either impossible or produces a price that makes private capital look attractive. The cost of the listing process — lawyers, bankers, auditors, listing fees — runs into the millions. The post-listing compliance burden — quarterly reporting, investor relations, board structure, governance — is substantial and permanent.

For most MedTech startups, the correct way to think about IPO is as a possible exit further down the line, after the company has scale, revenue, and a repeatable business. It is not a credible primary exit plan at seed or Series A. Telling an early investor that the plan is "grow to IPO" without a credible path to the revenue and margin profile that listings require is a signal that the founder has not done the exit math.

This does not mean IPO is never right. For the handful of MedTech companies that reach meaningful revenue, a strong growth trajectory, and a story investors want, a listing can produce outcomes that M&A would not match. It just means IPO is a low-probability path that should be treated as optionality, not as the plan.

## Partnership-as-exit — the quiet third path

The exit mode founders pay the least attention to is the one that produces some of the best outcomes.

A strategic partnership with a larger player — co-development, exclusive distribution, licensing with a buy-in clause — lets a MedTech startup de-risk in stages. The first stage is commercial: the partner takes the product to market, the startup learns whether the go-to-market actually works, the relationship is tested on real operational issues. The second stage is financial: a buy-in or buy-out clause triggers at an agreed milestone — often a revenue threshold, sometimes a time window, occasionally a clinical milestone. The founder receives an agreed valuation without running a full M&A process.

The appeal for the acquirer is obvious: they get to test the relationship before committing the full cheque. The appeal for the founder is that the relationship becomes a strong signal to other potential acquirers, which creates competitive tension even in a structured deal. The risk, which has to be managed carefully, is that an exclusivity clause in the partnership agreement locks the founder out of better options if the partner underperforms. This is the same pattern as the exclusivity trap we described in [funding a MedTech startup](/blog/funding-medtech-startup), and it deserves the same careful negotiation.

Partnerships as exits require the same regulatory cleanliness as any other exit. The partner has to be able to rely on the CE certificate, the QMS, and the technical file. If the regulatory assets are shaky, the partnership structure does not fix it — it just pushes the problem into the buy-in clause, where it becomes an excuse to reduce the valuation at the moment of exercise.

## The founder dilemma

The hardest thing about exits is that the right exit for the founder is often not the right exit for every investor on the cap table, and the founder finds this out in the middle of the process when it is too late to restructure.

Early angels and grant funders usually have flexible return expectations. They can live with a modest trade sale in year seven. A Series B investor whose fund is structured for 10x returns cannot. A Series A investor who was promised an IPO will be quietly unhappy about a trade sale even if the trade sale is the best option on the table. When these expectations diverge, the exit process becomes a negotiation between co-owners before it becomes a negotiation with the acquirer — and the acquirer can sense the lack of alignment immediately.

The fix is upstream, at the point each investor joined the cap table. If you took investors who expected an IPO, you are implicitly committed to chasing an IPO even if it is the wrong path. If you took investors whose return requirements are incompatible with the exit landscape in your category, you have given yourself a structural problem that will surface at the worst possible moment.

This ties directly to the cap-table discipline in [funding a MedTech startup](/blog/funding-medtech-startup) and the capital-requirement reality in [why MedTech needs more capital than SaaS](/blog/medtech-more-capital-than-saas). The exit is not a separate problem from fundraising. It is the same problem, looked at from the other end.

## Common mistakes founders make at exit

A handful of specific errors repeat across MedTech exits. The patterns are consistent enough to name.

**Waiting for the offer before planning.** The founders who think about exit only when an acquirer calls have already lost the negotiation. The offer sets the frame, and the frame is always favourable to the acquirer.

**Treating regulatory as a back-office function rather than a transferable asset.** Founders who treat the QMS, the technical file, and the PMS system as cost centres rather than assets underprepare the documentation that acquirers actually value. At due diligence, the gaps become discount arguments.

**Fixating on one exit path too early.** Founders who plan exclusively for an IPO — or exclusively for a trade sale to a specific acquirer — close off optionality. Keep at least two paths credible until a real offer forces the choice.

**Mismatched investor expectations.** Taking capital from investors whose fund structures require outcomes your exit path cannot deliver. This problem is created at fundraising time and only becomes visible at exit.

**Unclean intellectual property.** IP that is assigned messily — contractor work never formally assigned, university IP never properly licensed, open-source components without clean licensing — becomes a deal blocker at due diligence. Fix it early.

**Letting the cap table drift.** Dead equity, unclear vesting, promised shares that were never documented — all of these surface at exit and reduce the valuation or blow up the deal. The fix is the same as in the funding context: clean cap-table hygiene from day one.

## The Subtract to Ship angle on exits

[Subtract to Ship](/blog/subtract-to-ship-framework-mdr) applied to exit strategy says the same thing it says everywhere else: remove the work that does not contribute to the outcome, keep the work that does, and trace every decision to something real.

For exits, the real things are: a clean regulatory asset, a credible product, a team the acquirer wants, a cap table that can actually close a transaction, and a founder who knows what they want from the outcome. Everything else is either noise or window-dressing. The elaborate investor decks, the aspirational exit valuations, the imaginary IPO in year seven — none of this matters if the underlying assets are not in order.

The founders who exit well are the ones who spent the pre-exit years building transferable assets, not the ones who spent those years pitching imaginary outcomes. That is the Subtract to Ship discipline applied to the end of the company, not just the beginning.

## Reality Check — Where do you stand?

1. If an acquirer made a serious offer tomorrow, is your technical file, QMS, and CE certificate status ready to survive regulatory due diligence without embarrassment?
2. Have you identified at least two credible exit paths for your company — not just one?
3. Do you know which investors on your cap table have return expectations incompatible with a trade-sale exit, and have you discussed this with them?
4. Is your intellectual property assigned cleanly, with no contractor gaps, no university-IP ambiguity, and no open-source licensing traps?
5. If a strategic partner offered a distribution deal with a buy-in clause today, do you know what terms you would accept and what terms you would refuse?
6. Have you thought about your own post-exit life — what you want, what you do not want, and whether a trade sale or an earn-out fits that?
7. When was the last time you looked at the company from the perspective of a potential acquirer, rather than from the perspective of a founder building it?

## Frequently Asked Questions

**What is the most common exit for a European MedTech startup?**
A trade sale to a strategic acquirer — often a larger MedTech company in the same therapeutic area, sometimes a private-equity-backed platform, occasionally a distributor moving upmarket. IPOs are rare. Strategic partnerships with buy-in clauses are the underrated third path and are more common than many founders realise.

**Can I transfer my CE certificate to the acquirer in an M&A deal?**
Yes, but the transfer is not automatic. The acquirer either takes over the legal manufacturer role under MDR Article 10 with all the accompanying obligations, or the product is re-branded under the acquirer's existing quality system. Either path requires Notified Body involvement and QMS updates, and both should be planned into the deal timeline before closing.

**Is an IPO a realistic exit plan for an early-stage MedTech startup?**
Rarely. European public markets have narrow and unstable windows for pre-profit MedTech listings. Listing costs run into the millions and post-listing compliance is substantial and permanent. IPO is best treated as remote optionality for companies that eventually reach scale and revenue, not as a primary exit plan at seed or Series A.

**How do regulatory assets affect valuation?**
Materially. A live QMS under EN ISO 13485:2016+A11:2021, a clean technical file, and a current CE certificate are transferable assets that save the acquirer months or years of work. Sophisticated acquirers price this into the offer. Messy regulatory assets create discount arguments at due diligence and can reduce the valuation significantly.

**What is the biggest mistake founders make at exit?**
Waiting for an offer before thinking about exit structure. By the time an acquirer calls, the leverage has already moved. The founders who exit well spent the pre-exit years building transferable assets and preserving multiple paths, not reacting to a single offer.

**Should I take an earn-out, or hold out for all-cash?**
It depends on the acquirer, the structure, and your confidence in the conditions that trigger the earn-out. Earn-outs are common in MedTech because acquirers want to align the founders with post-close performance. The risk is that the earn-out conditions are defined in ways that are hard to hit under the acquirer's operating decisions, leaving the seller worse off than an all-cash deal at a lower headline number would have been. Negotiate the conditions with the same care you negotiate the price.

## Related reading

- [CE Marking Cost for Startups: A Transparent Breakdown](/blog/ce-marking-cost-startup-transparent-breakdown) — the regulatory cost buckets that become transferable assets at exit.
- [The Subtract to Ship Framework for MDR](/blog/subtract-to-ship-framework-mdr) — the methodology applied throughout the lifecycle, including the approach to exit.
- [Product-Market Fit for MedTech Startups](/blog/product-market-fit-medtech-startups) — without PMF, no exit conversation is credible.
- [Funding a MedTech Startup](/blog/funding-medtech-startup) — the hub post whose cap-table decisions shape your exit options years later.
- [Why MedTech Needs More Capital Than SaaS](/blog/medtech-more-capital-than-saas) — the runway reality that determines which exits are reachable.
- [MedTech Business Models Explained](/blog/medtech-business-models) — the model choices that influence what kind of acquirer will find you attractive.
- [MedTech Reimbursement Strategy](/blog/medtech-reimbursement-strategy) — reimbursement credibility is a major component of the acquirer's valuation.
- [MedTech Go-to-Market Strategy](/blog/medtech-go-to-market-strategy) — commercial traction is what turns an interesting product into an acquirable company.
- [MedTech Distribution Partnerships](/blog/medtech-distribution-partnerships) — the companion view of partnership structures that can evolve into exits.
- [Valuing a MedTech Startup](/blog/valuing-medtech-startup) — the valuation mechanics behind every exit conversation.

## Sources

1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, Article 10 (manufacturer obligations relevant to change of legal manufacturer at exit). Official Journal L 117, 5.5.2017.
2. EN ISO 13485:2016 + A11:2021 — Medical devices — Quality management systems — Requirements for regulatory purposes (the transferable QMS asset).

---

*This post is part of the Funding, Business Models and Reimbursement series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. A MedTech exit is not a single event — it is the result of years of decisions about regulatory assets, cap table, IP, and positioning. Start early, keep the paths open, and let the work speak for itself when the offer arrives.*

---

*This post is part of the [Funding, Business Models & Reimbursement](https://zechmeister-solutions.com/en/blog/category/funding-reimbursement) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*